EI

232.5

-0.85%↓

MRK1

138.5

+0.04%↑

SHL.DE

49.09

-1.29%↓

ARGX

563.4

+1.48%↑

UCB

174.15

+2.47%↑

EI

232.5

-0.85%↓

MRK1

138.5

+0.04%↑

SHL.DE

49.09

-1.29%↓

ARGX

563.4

+1.48%↑

UCB

174.15

+2.47%↑

EI

232.5

-0.85%↓

MRK1

138.5

+0.04%↑

SHL.DE

49.09

-1.29%↓

ARGX

563.4

+1.48%↑

UCB

174.15

+2.47%↑

EI

232.5

-0.85%↓

MRK1

138.5

+0.04%↑

SHL.DE

49.09

-1.29%↓

ARGX

563.4

+1.48%↑

UCB

174.15

+2.47%↑

EI

232.5

-0.85%↓

MRK1

138.5

+0.04%↑

SHL.DE

49.09

-1.29%↓

ARGX

563.4

+1.48%↑

UCB

174.15

+2.47%↑

Search

Sanofi SA

Abierto

Sector Salud

90.88 0.04

Resumen

Variación precio

24h

Actual

Mínimo

90.2

Máximo

91.02

Métricas clave

By Trading Economics

Ingresos

1.7B

2.8B

Ventas

2.1B

13B

P/B

Media del Sector

30.62

94.998

BPA

2.86

Rentabilidad por dividendo

3.944

Margen de beneficio

20.945

EBITDA

2.2B

4.2B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+23.16 upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.94%

2.40%

Próximas Ganancias

30 ene 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

113B

Apertura anterior

90.84

Cierre anterior

90.88

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

100 / 392 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

Sanofi SA Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

15 nov 2024, 10:28 UTC

Principales Movimientos del Mercado

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

29 oct 2024, 10:07 UTC

Ganancias

Santander's Profit Beats Expectations on Lower Provisions, Costs -- Update

29 oct 2024, 06:37 UTC

Ganancias

Santander's Profit Beats View Despite Lower-Than-Expected Revenue

28 oct 2024, 16:07 UTC

Adquisiciones, fusiones, absorciones

AbbVie to Acquire Aliada Therapeutics for $1.4 Billion -- Update

25 oct 2024, 05:44 UTC

Ganancias

Sanofi Profit, Sales Beat Estimates

15 nov 2024, 13:08 UTC

Principales Noticias

Trump's RFK Pick Weighs on Vaccine Makers -- WSJ

15 nov 2024, 10:34 UTC

Charlas de Mercado

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

15 nov 2024, 10:29 UTC

Acciones populares

Stocks to Watch Friday: Tesla, Domino's, Palantir, Ulta -- WSJ

14 nov 2024, 11:29 UTC

Charlas de Mercado
Ganancias

European Banks' Results Confirm Earnings Momentum -- Market Talk

4 nov 2024, 11:42 UTC

Charlas de Mercado

European Banks Exposed to Trade Tariffs Outcome From U.S. Election -- Market Talk

29 oct 2024, 13:16 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Conditions Lack for Attractive European Cross-Border M&A Deals, Santander CEO Says -- Market Talk

29 oct 2024, 07:02 UTC

Charlas de Mercado

Santander's Take on Brazil Rates, Motor-Finance Issue in Focus -- Market Talk

29 oct 2024, 05:52 UTC

Ganancias

Santander Backs 2024 View

29 oct 2024, 05:52 UTC

Ganancias

Santander: If All Targets Are Met, Total Remuneration Against 2024 Results Over EUR6B

29 oct 2024, 05:51 UTC

Ganancias

Santander Confident on Delivering on Targets

29 oct 2024, 05:50 UTC

Ganancias

Analysts Saw Santander End-3Q Fully Loaded CET1 Ratio 12.5%

29 oct 2024, 05:50 UTC

Ganancias

Santander End-3Q Fully Loaded CET1 Ratio 12.5%

29 oct 2024, 05:49 UTC

Ganancias

Analyst Saw Santander 3Q Net Interest Income EUR11.59B

29 oct 2024, 05:49 UTC

Ganancias

Santander 3Q Net Interest Income EUR11.225B

29 oct 2024, 05:48 UTC

Ganancias

Analysts Saw Santander 3Q Net Loan Loss Provisions EUR3.17B

29 oct 2024, 05:48 UTC

Ganancias

Santander 3Q Net Loan Loss Provisions EUR2.98B

29 oct 2024, 05:48 UTC

Ganancias

Analysts Saw Santander 3Q Net Pft EUR3.17B

29 oct 2024, 05:48 UTC

Ganancias

Santander 3Q Net Pft EUR3.25B

29 oct 2024, 05:48 UTC

Ganancias

Santander 3Q Rev EUR15.135B

29 oct 2024, 05:48 UTC

Ganancias

Analysts Saw Santander 3Q Rev EUR15.31B

28 oct 2024, 08:18 UTC

Charlas de Mercado

Banks' Risks From U.K. Motor Finance Probe Rise -- Market Talk

25 oct 2024, 20:25 UTC

Ganancias

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

25 oct 2024, 13:12 UTC

Ganancias

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

25 oct 2024, 07:00 UTC

Charlas de Mercado
Ganancias
Adquisiciones, fusiones, absorciones

Sanofi's 3Q Results Show Solid Vaccine Performance -- Market Talk

25 oct 2024, 05:30 UTC

Ganancias

Sanofi 3Q Adj EPS EUR2.86

Comparación entre iguales

Cambio de precio

Sanofi SA Esperado

Precio Objetivo

By TipRanks

23.16% repunte

Estimación a 12 meses

Media 112.335 EUR  23.16%

Máximo 130 EUR

Mínimo 90 EUR

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sanofi SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

13 ratings

9

Comprar

3

Mantener

1

Vender

Puntuación técnica

By Trading Central

90.82 / 95.65Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

100 / 392 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Sanofi SA

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.